

## PRODUCT WITHDRAWAL



**Instanyl Multi-dose 50 micrograms/dose nasal spray, solution**  
**Instanyl Multi-dose 100 micrograms/dose nasal spray, solution**  
**Instanyl Multi-dose 200 micrograms/dose nasal spray, solution**

**EU/1/09/531/001-009**

1st November 2018

Dear Healthcare Professional

As the Marketing Authorisation Holder (MAH) for Instanyl Multi-dose nasal spray, Takeda has made the decision to withdraw the product for all multi-dose strengths in the United Kingdom from the 14<sup>th</sup> December 2018. This decision has been made for commercial reasons and means that the multi-dose product will no longer be available for use.

Instanyl Multi-dose is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. The active ingredient in Instanyl Multi-dose is fentanyl citrate.

Alternative fentanyl citrate products indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain are available in the UK. Alternative products include, single dose intranasal preparations, sublingual tablets and buccal tablets. Please note that the Instanyl single dose presentation will remain available.

Please note that fentanyl preparations for the treatment of BTP are not interchangeable. Any patient being treated with Instanyl Multi-dose should be referred back to their treating physician for consideration of an alternate preparation. If patients are switched from Instanyl Multi-dose to another fentanyl preparation, a new dose titration is required.

**No new patients should be prescribed Instanyl Multi-dose from the date of this notification.**

Should you have any questions regarding the use of Instanyl Multi-dose nasal spray or questions about the content of this letter, please contact Takeda:

Takeda UK Ltd, Building 3, Glory Park Avenue, Wooburn Green, High Wycombe, Bucks, HP10 0DF  
Tel: +44 1628 537900, Fax: +44 1628 526615, Email: [DSO-UK@takeda.com](mailto:DSO-UK@takeda.com),  
Website: [www.takeda.co.uk](http://www.takeda.co.uk)

We thank you for your attention and understanding.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Simon Meadowcroft".

Dr Simon Meadowcroft

Medical Director

Takeda UK Ltd

Building 3, Glory Park Avenue, Wooburn Green, High Wycombe, Bucks, HP10 0DF

Phone: +44(0)1628 537 971 Email: [simon.meadowcroft@takeda.com](mailto:simon.meadowcroft@takeda.com)

### **Takeda UK Ltd.**

Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Bucks HP10 0DF, United Kingdom  
Tel +44 (0)1628 537900 Fax +44 (0)1628 526615 [www.takeda.co.uk](http://www.takeda.co.uk)  
Registered in England and Wales No. 3362860